

Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — What Happened at ASH 2025?

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following best describes the 5-year progression-free survival (PFS) rate for patients in a pivotal Phase II study who achieved a complete response with mosunetuzumab for relapsed/refractory (R/R) follicular lymphoma (FL) after 2 or more prior therapies?

- a. Higher than 25%
- b. Higher than 50%**
- c. Higher than 75%
- d. Higher than 90%

2. In the 3-year follow-up of the Phase III STARGLO trial, the combination of glofitamab and gemcitabine/oxaliplatin resulted in which of the following outcomes in comparison to rituximab with gemcitabine/oxaliplatin for patients with transplant-ineligible R/R diffuse large B-cell lymphoma (DLBCL)?

- a. Inferior overall survival (OS)
- b. Noninferior OS
- c. Significantly improved OS**
- d. OS has not yet been reported

3. What was the approximate objective response rate in the 3-year follow-up of the Phase II ELM-2 trial of odrnextamab monotherapy for patients with R/R DLBCL?

- a. 50%
- b. 65%
- c. 80%**
- d. 90%

4. The Phase III EPCORE FL-1 trial evaluating epcoritamab, rituximab and lenalidomide versus rituximab and lenalidomide for patients with R/R FL reported which of the following efficacy outcomes with the epcoritamab triplet?

- a. Inferior independent review committee PFS (IRC-PFS)
- b. Noninferior IRC-PFS**
- c. Significantly improved IRC-PFS**
- d. Data have not yet been reported

5. Which of the following adverse events is the most common noted with the combination of glofitamab with golcadomide among patients with R/R B-cell non-Hodgkin lymphoma?

- a. Cytokine release syndrome**
- b. Headache**
- c. Injection site reaction**
- d. Neutropenia**